Perspective Therapeutics Inc. (NYSE MKT:CATX) — Market Cap & Net Worth
Market Cap & Net Worth: Perspective Therapeutics Inc. (CATX)
Perspective Therapeutics Inc. (NYSE MKT:CATX) has a market capitalization of $442.39 Million ($442.39 Million) as of July 8, 2026. Listed on the NYSE MKT stock exchange, this USA-based company holds position #12848 globally and #3132 in its home market, demonstrating a 3.11% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Perspective Therapeutics Inc.'s stock price $3.98 by its total outstanding shares 114017755 (114.02 Million). See CATX capex reinvestment rate to understand how much of operating cash flow is reinvested back into capital assets.
Perspective Therapeutics Inc. Market Cap History: 2015 to 2026
Perspective Therapeutics Inc.'s market capitalization history from 2015 to 2026. Data shows change from $1.07 Billion to $453.79 Million (-11.49% CAGR).
Perspective Therapeutics Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Perspective Therapeutics Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
354.69x
Perspective Therapeutics Inc.'s market cap is 354.69 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $513.08 Million | $10.05 Million | -$3.19 Million | 51.04x | N/A |
| 2020 | $513.08 Million | $9.68 Million | -$3.27 Million | 53.00x | N/A |
| 2021 | $444.67 Million | $10.79 Million | -$7.27 Million | 41.19x | N/A |
| 2021 | $444.67 Million | $10.05 Million | -$3.19 Million | 44.23x | N/A |
| 2022 | $285.04 Million | $7.10 Million | -$14.67 Million | 40.12x | N/A |
| 2022 | $285.04 Million | $10.79 Million | -$7.15 Million | 26.41x | N/A |
| 2023 | $456.07 Million | $1.43 Million | -$46.51 Million | 318.04x | N/A |
| 2023 | $456.07 Million | $7.10 Million | -$14.67 Million | 64.20x | N/A |
| 2025 | $313.55 Million | $884.00K | -$103.12 Million | 354.69x | N/A |
Competitor Companies of CATX by Market Capitalization
Companies near Perspective Therapeutics Inc. in the global market cap rankings as of July 8, 2026.
Key companies related to Perspective Therapeutics Inc. by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #142 globally with a market cap of $166.65 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #188 globally with a market cap of $126.19 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #232 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
- Medtronic PLC (NYSE:MDT): Ranked #239 globally with a market cap of $103.60 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #142 | Abbott Laboratories | NYSE:ABT | $166.65 Billion | $95.84 |
| #188 | Stryker Corporation | NYSE:SYK | $126.19 Billion | $329.74 |
| #232 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
| #239 | Medtronic PLC | NYSE:MDT | $103.60 Billion | $83.83 |
Perspective Therapeutics Inc. Historical Marketcap From 2015 to 2026
Between 2015 and today, Perspective Therapeutics Inc.'s market cap moved from $1.07 Billion to $ 453.79 Million, with a yearly change of -11.49%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $453.79 Million | +44.73% |
| 2025 | $313.55 Million | -13.79% |
| 2024 | $363.72 Million | -20.25% |
| 2023 | $456.07 Million | +60.00% |
| 2022 | $285.04 Million | -35.90% |
| 2021 | $444.67 Million | -13.33% |
| 2020 | $513.08 Million | -27.42% |
| 2019 | $706.91 Million | +106.67% |
| 2018 | $342.05 Million | -25.00% |
| 2017 | $456.07 Million | -31.03% |
| 2016 | $661.30 Million | -38.30% |
| 2015 | $1.07 Billion | -- |
End of Day Market Cap According to Different Sources
On Jul 8th, 2026 the market cap of Perspective Therapeutics Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $442.39 Million USD |
| MoneyControl | $442.39 Million USD |
| MarketWatch | $442.39 Million USD |
| marketcap.company | $442.39 Million USD |
| Reuters | $442.39 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Perspective Therapeutics Inc.
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors t… Read more